Revvity Developing Automated Platform for Tuberculosis Testing
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
Latest Articles
Editor's Top Picks
Blood Circular RNAs Outperform pTau217 in Predicting Alzheimer’s Disease Progression
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
Cancer Cell Diagnostics Launches New Blood Test for Cancer Profiling
The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.
Equipment & Supply Spotlight
Roche Receives CE Mark for Tuberculosis Blood Test
The automated assay identifies latent infections in routine laboratory settings with results available in less than 24 hours.
News, Know-How & Standards
Disease Detection & Understanding
Protein Biomarker May Predict Sjögren’s Disease Years Before Symptoms
A new ultrasensitive blood test may detect Sjögren’s disease more than 10 years before symptoms appear by identifying chronically elevated interferon alpha levels in patient blood samples.
